Saturday 17 October 2026 Export ENSC’s income statement to Excel — free account

Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.1 million, down 2.75% from fiscal 2024. In the quarter to June 2026, revenue fell 15.1%, EPS grew 74.7% and free cash flow grew 27.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.52 0.08 −13.33%

Follow ENSC

Alert me

Market cap: $11.6M
P/E: 0.0×
Fwd P/E: −0.1×
Dividend yield: —
F-score: 3/9
Altman Z: −29.36
Beneish M: −1.90
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.44

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	1	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 11.64

Revenue 4.50

Net Income (12.62)

Free Cash Flow (8.86)

Net Debt (0.68)

Current Ratio 0.70

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.13)

P/S ratio 1.51

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 72.61%

Next Y EPS Growth 94.50%

Next Y revenue growth (9.21%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 56.46%

10-year low 10-year high

EV/Sales against its own 10 years 62.65%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1	4	4	1
Receivables	0	0	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	2	5	7	3

	2023	2024	2025	Q'26
Payables	2	1	3	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	3	2	5	4

Compound Annual Growth %

	10y	5y	3y
Sales	—	5.21%	26.16%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	1	1	0	2	5
’24	0	0	3	1	5
’23	1	0	0	1	2
’22	1	0	0	1	3
’21	0	0	1	2	4

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(2)	—	—	—
’25	(2)	(3)	(2)	(2)	(8)
’24	(3)	(2)	(1)	(1)	(8)
’23	(4)	(3)	(2)	(2)	(11)
’22	(3)	(4)	(7)	(3)	(18)
’21	(1)	0	(4)	(4)	(8)
’20	0	0	0	(1)	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(2)	—	—	—
’25	(2)	(3)	(2)	(2)	(8)
’24	(3)	(2)	(1)	(1)	(8)
’23	(4)	(3)	(2)	(2)	(11)
’22	(3)	(4)	(7)	(3)	(18)
’21	(1)	0	(4)	(4)	(8)
’20	0	0	0	(1)	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.52)	(0.20)	—	—	—
’25	(1.39)	(0.79)	(1.29)	(0.75)	(3.98)
’24	(8.25)	(3.30)	1.05	(2.90)	(11.45)
’23	(31.18)	(14.69)	(13.04)	(16.94)	(70.31)
’22	(215.98)	(863.91)	(923.31)	(273.57)	(2.09k)
’21	(207.26)	(215.98)	(2.56k)	(1.62k)	(5.33k)
’20	1.01k	(161.27)	331.25	(1.22k)	(35.08)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	34,380.00	35,352.00	32,814.00	4,500.00	106.20	11.48	2.12	0.86	Analyst estimates 2026–2028 Powerpack
	High	—	—	35,460.00	37,548.00	49,226.40	86,364.00	18,144.00	275.40	30.90	9.57
People
People	Employees	—	4	4	4	4	6	7	8	7	10
	Revenue/emp, $m	—	0.00	0.00	0.00	0.98	0.59	0.36	0.28	0.74	0.51
Income, $m
Income, $m	Revenue	—	—	—	—	4	4	3	2	5	5
	Gross margin, %	—	—	—	—	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	0	3	(1)	0	(29)	(24)	(11)	(8)	(10)
	EBT margin, %	—	0.00	0.00	0.00	(4.09)	(825.38)	(959.33)	(476.41)	(153.30)	(200.84)
	Net income	—	0	2	(1)	0	(29)	(24)	(11)	(8)	(10)
	Depreciation	—	—	—	—	0	0	—	0	1	0
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	893.45	630.57	210.28	14.77	7.46	1.98
	Earnings	—	0.00	1,272.46	(631.68)	1,323.40	(5,327.47)	(2,091.39)	(70.31)	(11.45)	(3.98)
	Cash flow	—	(0.20)	(728.41)	(838.12)	(283.48)	(1,471.82)	(1,490.62)	(71.39)	(10.75)	(3.05)
	Capex	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(0.05)
	Free cash flow	—	(0.20)	(728.41)	(838.12)	(283.48)	(1,471.82)	(1,490.62)	(71.39)	(10.75)	(3.10)
	Book value	—	3.97	2,941.18	2,941.18	(1,513.27)	(1,456.80)	(335.81)	(4.31)	4.84	1.13
	Shares, m	—	1	0	0	0	0	0	0	1	3
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	0.00	26.83	0.68	1.13	1.09	0.46
	P/B	—	—	—	—	0.00	0.00	0.00	0.00	1.68	0.82
	EV/Sales	—	—	—	—	0.00	24.81	(0.24)	0.99	0.57	(0.23)
	EV/FCF	—	—	—	—	(158.93)	(10.63)	0.03	(0.20)	(0.40)	0.15
Cash, $m
Cash, $m	Operating cash flow	—	0	(1)	(1)	(1)	(8)	(18)	(11)	(8)	(8)
	Capex	—	—	—	—	—	—	—	—	—	0
	Free cash flow	—	0	(1)	(1)	(1)	(8)	(18)	(11)	(8)	(8)
Balance, $m
Balance, $m	Working capital	—	2	1	(2)	(7)	(1)	(4)	(1)	3	3
	Total debt	—	—	—	1	1	4	0	—	—	—
	Net debt	—	(2)	(2)	0	1	(8)	(3)	(1)	(4)	(4)
	Shareholders’ equity	—	5	5	5	(7)	(8)	(4)	(1)	3	3
Returns, %
Returns, %	ROA	—	(0.02)	1.04	(0.53)	0.06	(356.45)	(224.96)	(247.31)	(192.34)	(155.95)
	ROIC	—	0.00	(17.94)	(46.18)	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	(0.62)	42.44	(21.35)	(6.85)	403.43	411.65	454.02	(585.44)	(324.86)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AEON AEON Biopharma, Inc.	$12.1M	— (loss-making)	—	—	n/m	−76.85% (below 0%: shrinking)	—	0.00%	Compare
ASBP Aspire-Lakewood Holdings, Inc.	$12.1M	0.2×	—	—	n/m	−85.54% (below 0%: shrinking)	(47.70%)	(4,244.37%)	Compare
ACTU Actuate Therapeutics, Inc.	$12.0M	— (loss-making)	—	—	n/m	−5.54% (below 0%: shrinking)	—	0.00%	Compare
PLUR Pluri Inc.	$11.9M	— (loss-making)	— (loss-making)	−15.83% (below 0%: shrinking)	n/m	+25.03% (above 0%: growing)	58.51%	(1,655.52%)	Compare
INAB IN8bio, Inc.	$11.7M	— (loss-making)	—	—	n/m	−1.30% (below 0%: shrinking)	0.00%	0.00%	Compare
ENSC Ensysce Biosciences, Inc.	$11.6M	— (loss-making)	— (loss-making)	−15.10% (below 0%: shrinking)	n/m	+27.50% (above 0%: growing)	100.00%	(221.28%)
PASG Passage Bio, Inc.	$11.6M	— (loss-making)	—	—	n/m	−59.81% (below 0%: shrinking)	0.00%	0.00%	Compare
PTN Palatin Technologies, Inc.	$11.6M	— (loss-making)	0.2×	−14.06% (below 0%: shrinking)	n/m	+34.21% (above 0%: growing)	100.00%	(1,469.35%)	Compare
CLRB Cellectar Biosciences, Inc.	$11.2M	— (loss-making)	—	−73.23% (below 0%: shrinking)	n/m	−17.49% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$11.8M	—	—	−15.83%	—	−11.51%	0.00%	0.00%

All 614 Biotechnology stocks →

Ensysce Biosciences, Inc. (ENSC) key facts

Concern: Ensysce Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.1 million, down 2.75% from fiscal 2024.
Ensysce Biosciences, Inc. (ENSC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ENSC traded at $0.52, a market capitalization of $11.6 million.
Return on equity was −324.9% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −29.36 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.